Elritercept versus placebo for myelofibrosis anemia on ruxolitinib
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests whether a new drug called elritercept can help reduce the need for blood transfusions in adults with myelofibrosis (a bone marrow cancer) who are already taking ruxolitinib. The goal is to see if elritercept helps your body make more red blood cells naturally.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and diagnosed with myelofibrosis (primary, post-ET, or post-PV type)
- You have received 3 to 8 units of red blood cell transfusions in the past 12 weeks
- You have been on a stable dose of ruxolitinib for at least 8 weeks
- You are in good enough health to participate (ECOG score 0, 1, or 2)
- You have not previously taken luspatercept, sotatercept, or similar drugs
- Your blood counts and organ function meet specific safe ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether elritercept, given alone or together with ruxolitinib, can improve symptoms and disease control in adults with myelofibrosis. It may help people who have anemia and either cannot tolerate, can’t get enough benefit from, or are already using ruxolitinib.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This trial tests whether adding a drug called interferon alfa-2b to the standard treatment ruxolitinib can help people with myelofibrosis. It may reduce spleen size and improve blood counts.
This trial compares two oral drugs, momelotinib and ruxolitinib, for people with myelofibrosis who have low blood cell counts. Both drugs aim to reduce an enlarged spleen and improve symptoms, and this study will see which one works better and with fewer side effects.
This trial tests a new drug called Navtemadlin when added to the standard treatment ruxolitinib for people with myelofibrosis who are not getting the best results from ruxolitinib alone. It may help improve response and control the disease.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.